AmCad BioMed Corporation (TPEX:4188)
Taiwan · Delayed Price · Currency is TWD 9.48
-0.17 (-1.76%)
Jul 30, 2026, 1:30 PM CST
AmCad BioMed Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 30.04 | 30.44 | 53.11 | 65.26 | 61.63 | 85.79 |
Revenue Growth | -42.01% | -42.69% | -18.62% | 5.88% | -28.16% | 34.17% |
Gross Profit Gross Profit Growth | 10.74 | 10.02 | 32.93 | 41.02 | 38.05 | 60.67 |
Operating Income Operating Income Growth | -84.96 | -87.96 | -64.66 | -53.99 | -64.3 | -36.77 |
Net Income Net Income Growth | -53.66 | -55.72 | -50.58 | -45.31 | -53.49 | -25.54 |
Earnings Per Share EPS Growth | -0.85 | -0.88 | -0.88 | -0.85 | -1.01 | -0.48 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Precise Medical Devices Precise Medical Devices Growth | 20 | 21.31 | 41.4 | 52.9 | 51.05 | 52.13 |
Medical Diagnostic Software Medical Diagnostic Software Growth | 10.05 | 9.13 | 11.7 | 12.36 | 10.58 | 33.66 |
Total Total Growth | 30.04 | 30.44 | 53.11 | 65.26 | 61.63 | 85.79 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 349.19 | 365.22 | 361.71 | 287.27 | 330.84 | 371.05 |
Total Debt Total Debt Growth | 14.5 | 4.75 | 10.87 | 14.39 | 10.31 | 14.73 |
Net Cash (Debt) Net Cash Growth | 334.69 | 360.47 | 350.84 | 272.88 | 320.53 | 356.32 |
Net Cash Growth | -16.05% | 2.75% | 28.57% | -14.87% | -10.04% | -8.84% |
Net Cash Per Share Net Cash Per Share Growth | 5.28 | 5.69 | 6.08 | 5.13 | 6.02 | 6.70 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -46.91 | -47.06 | -51.85 | -41.6 | -34.19 | -38.97 |
Capital Expenditures CapEx Growth | -0.2 | -0.37 | -2.72 | -0.29 | -0.61 | -2.34 |
Free Cash Flow Free Cash Flow Growth | -47.11 | -47.44 | -54.57 | -41.89 | -34.81 | -41.3 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 35.73% | 32.93% | 62.02% | 62.87% | 61.73% | 70.71% |
Operating Margin | -282.80% | -288.97% | -121.77% | -82.73% | -104.33% | -42.86% |
Pretax Margin | -227.55% | -234.59% | -99.57% | -66.12% | -88.18% | -31.34% |
Profit Margin | -178.59% | -183.06% | -95.24% | -69.44% | -86.79% | -29.78% |
FCF Margin | -156.80% | -155.85% | -102.76% | -64.20% | -56.48% | -48.14% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 19.98 | 30.59 | 26.66 | 21.79 | 13.77 | 12.00 |